• Press Releases
  • Study Finds Half of Patients with Low-Grade Proteinuria Develop Treatable Lupus Nephritis within Two Years

Study Finds Half of Patients with Low-Grade Proteinuria Develop Treatable Lupus Nephritis within Two Years

November 9, 2022 | ACR Convergence


ATLANTA — New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, found that 50% of people with low-grade proteinuria, which is protein in your urine, progress to clinical proteinuria within two years and show treatable lupus nephritis on biopsies. These “fast progressors” may benefit from early biopsies to detect lupus nephritis sooner, although further studies — the next step — are needed to confirm this (Abstract #1463).

Lupus nephritis, a complication of systemic lupus erythematosus (SLE, lupus), causes considerable morbidity and mortality. Kidney biopsy remains the gold standard for diagnosis of lupus nephritis and current guidelines recommend a biopsy for proteinuria equal to or greater than 0.5 gram a day (with or without active urinary sediment). However, some patients may have ongoing inflammation when they first present with low-grade proteinuria and may potentially have irreversible kidney damage by their first biopsy. This study aimed to assess proteinuria progression in patients with low-grade proteinuria — 0.2 to 0.5 urine protein to creatinine (UPCR) — and identify risk factors for progression to clinical proteinuria equal to or greater than 0.5 gram per day.

SLE patients with low-grade proteinuria but without known lupus nephritis were identified from the Einstein Rheumatic Disease Registry. Those who developed a UPCR equal to or greater than 0.5 during follow-up were defined as “progressors.” A subgroup who progressed to UPCR equal to or greater than 0.5 within two years were defined as “fast progressors.”

In this cohort, more than half of SLE patients with low-grade proteinuria progressed to clinical proteinuria, and 16 of 20 biopsies performed in the first two years indicated treatable lupus nephritis.

“Fast progressors may benefit from early biopsy because they progress more quickly and therefore may have active inflammation at the time of low-grade proteinuria. That was the reason for looking at this subgroup, but it was also important to know how many people progress eventually,” explains Anna Broder, MD, MS, a rheumatologist with Hackensack Meridian Medical Group and the study’s lead author. “Early lupus nephritis diagnosis and effective intervention reduce long-term adverse kidney complications.”

The researchers found that factors such as low complement, recent lupus onset, and younger age were associated with progression from low-grade to clinical proteinuria. However, the study wasn’t designed to show whether early biopsies or treating low-grade proteinuria slow the progression to kidney disease, end-stage kidney disease, or death. It also didn’t assess whether medications such as hydroxychloroquine and ACE inhibitors delay the onset of proteinuria in SLE patients.

“These critical questions will need to be addressed using randomized trials or large-scale pharmacoepidemiologic studies to minimize biases inherent in retrospective studies,” says Dr. Broder.

The study’s retrospective design led to other limitations.

“In particular, proteinuria was measured only by the protein to creatinine ratio. Although widely used, this is not the most accurate way to measure proteinuria. Biopsies were [also] not performed or were delayed for some patients for a variety of reasons, including differences in biopsy threshold guidelines over the years; patient preferences; socioeconomic barriers to care or insurance; high risk of complications and severe multiorgan disease requiring rapid escalation of immunosuppression for non-kidney manifestations. We could not determine if delays in biopsies resulted in higher chronicity,” says Dr. Broder.

Still, Dr. Broder says data from the current study lays the groundwork for future studies of the underlying molecular pathways involved in the progression of early lupus nephritis by identifying at-risk populations — work spearheaded by the Accelerating Medicines Partnership (AMP) initiative, a collaborative effort between the National Institutes of Health (NIH) and leading U.S. centers.

This research was supported by the National Center for Advancing Translational Science (NCATS) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).


Media Contact
Amanda Head

About ACR Convergence
ACR Convergence, the annual meeting of the American College of Rheumatology, is where rheumatology meets to collaborate, celebrate, congregate, and learn. With more than 320 sessions and thousands of abstracts, it offers a superior combination of basic science, clinical science, business education and interactive discussions to improve patient care. For more information about the meeting, visit the ACR Convergence page, or join the conversation on Twitter by following the official hashtag (#ACR22).

About the American College of Rheumatology
Founded in 1934, the American College of Rheumatology (ACR) is a not-for-profit, professional association committed to advancing the specialty of rheumatology that serves nearly 8,500 physicians, health professionals, and scientists worldwide. In doing so, the ACR offers education, research, advocacy and practice management support to help its members continue their innovative work and provide quality patient care. Rheumatology professionals are experts in the diagnosis, management and treatment of more than 100 different types of arthritis and rheumatic diseases.

We use cookies on our website to improve our service to you and for security purposes. By continuing to use our site without changing your browser cookie settings, you agree to our cookie policy and the use of cookies. See ACR Policies